Critical Review: NeuroOne Medical Technologies (NASDAQ:NMTC) and PolyPid (NASDAQ:PYPD)
Critical Review: NeuroOne Medical Technologies (NASDAQ:NMTC) and PolyPid (NASDAQ:PYPD)
NeuroOne Medical Technologies (NASDAQ:NMTC – Get Rating) and PolyPid (NASDAQ:PYPD – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, profitability and risk.
纳斯达克：NMTC-GET Rating和纳斯达克：PYPD-GET Rating都是小盘医疗公司，但哪一家的业务更好？我们将根据这两家公司的收益、分析师建议、股息、机构所有权、估值、盈利能力和风险等方面的实力进行比较。
Profitability
盈利能力
This table compares NeuroOne Medical Technologies and PolyPid's net margins, return on equity and return on assets.
此表比较了NeuroOne医疗技术公司和PolyPid的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| NeuroOne Medical Technologies | -7,177.71% | -97.47% | -88.76% |
| PolyPid | N/A | -193.77% | -128.47% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| NeuroOne医疗技术 | -7,177.71% | -97.47% | -88.76% |
| PolyPid | 不适用 | -193.77% | -128.47% |
Institutional & Insider Ownership
机构与内部人持股
2.6% of NeuroOne Medical Technologies shares are owned by institutional investors. 7.6% of NeuroOne Medical Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
NeuroOne Medical Technologies 2.6%的股份由机构投资者持有。NeuroOne Medical Technologies 7.6%的股份由内部人士持有。强大的机构持股表明，对冲基金、大型基金管理公司和捐赠基金相信，一只股票有望实现长期增长。
Volatility & Risk
波动性与风险
Valuation and Earnings
估值和收益
This table compares NeuroOne Medical Technologies and PolyPid's revenue, earnings per share (EPS) and valuation.
此表比较了NeuroOne医疗技术公司和PolyPid的收入、每股收益(EPS)和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroOne Medical Technologies | $180,000.00 | 139.58 | -$9.95 million | ($0.76) | -2.04 |
| PolyPid | N/A | N/A | -$42.60 million | ($2.43) | -0.31 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| NeuroOne医疗技术 | $180,000.00 | 139.58 | -995万美元 | ($0.76) | -2.04 |
| PolyPid | 不适用 | 不适用 | -4,260万美元 | ($2.43) | -0.31 |
NeuroOne Medical Technologies has higher revenue and earnings than PolyPid. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.
NeuroOne医疗技术公司的收入和收益比PolyPid更高。NeuroOne Medical Technologies的市盈率低于PolyPid，这表明它目前是两只股票中更负担得起的一只。
Analyst Ratings
分析师评级
This is a summary of recent recommendations and price targets for NeuroOne Medical Technologies and PolyPid, as provided by MarketBeat.
这是由MarketBeat提供的对NeuroOne医疗技术公司和PolyPid的最近建议和目标价格的摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroOne Medical Technologies | 0 | 1 | 1 | 0 | 2.50 |
| PolyPid | 0 | 1 | 3 | 0 | 2.75 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| NeuroOne医疗技术 | 0 | 1 | 1 | 0 | 2.50 |
| PolyPid | 0 | 1 | 3 | 0 | 2.75 |
NeuroOne Medical Technologies presently has a consensus price target of $2.63, indicating a potential upside of 69.35%. PolyPid has a consensus price target of $11.63, indicating a potential upside of 1,444.23%. Given PolyPid's stronger consensus rating and higher possible upside, analysts plainly believe PolyPid is more favorable than NeuroOne Medical Technologies.
NeuroOne Medical Technologies目前的共识目标价为2.63美元，表明潜在涨幅为69.35%。PolyPid的普遍目标价为11.63美元，表明潜在上行空间为1,444.23%。考虑到PolyPid更高的共识评级和更高的可能上行空间，分析师显然认为PolyPid比NeuroOne医疗技术公司更有利。
Summary
摘要
NeuroOne Medical Technologies beats PolyPid on 7 of the 13 factors compared between the two stocks.
NeuroOne Medical Technologies在两只股票之间进行比较的13个因素中，有7个超过了PolyPid。
About NeuroOne Medical Technologies
关于NeuroOne医疗技术公司
(Get Rating)
(获取评级)
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
NeuroOne医疗技术公司是一家医疗技术公司。该公司专注于薄膜电极技术的开发和商业化，用于连续脑电(CEEG)和立体脑电(SEEG)记录、脊髓刺激、脑刺激和用于癫痫、帕金森病、肌张力障碍、特发性震颤、背部手术失败导致的慢性疼痛和其他相关神经疾病患者的消融解决方案。它与RBC医疗创新公司建立了战略合作伙伴关系，开发了一种射频消融发生器，与NeuroOne的组合记录和消融电极一起使用，以记录大脑活动并使用相同的电极消融脑组织。该公司总部设在明尼苏达州的伊甸园草原。
About PolyPid
关于PolyPid
(Get Rating)
(获取评级)
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
PolyPid有限公司是一家处于后期阶段的生物制药公司，开发、制造和销售基于聚合物-脂质胶囊基质(PLEX)平台的产品，以满足未得到满足的医疗需求。它的主要候选产品是D-PLEX100，这是一种用于预防胸骨(骨)手术部位感染(SSI)以及预防腹部(软组织)SSI的第三阶段临床试验。PolyPid有限公司成立于2008年，总部设在以色列佩塔提克瓦。
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
接受NeuroOne医疗技术日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对NeuroOne Medical Technologies和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。